Literature DB >> 26767002

Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy: Comparison of different cancer staging systems.

Qifeng Wang1, Wencheng Zhang1, Xiao Liu1, Xun Zhang2, Jie He3, Qinfu Feng1, Zongmei Zhou1, Lvhua Wang1, Weibo Yin1, Zefen Xiao1.   

Abstract

BACKGROUND: The 7th edition American Joint Committee on Cancer tumor-node-metastasis (AJCC TNM) staging system was published in 2010. Here we evaluate its predictive ability and compare the 6th and 7th editions of the AJCC TNM staging systems in esophageal squamous cell cancer (ESCC) with preoperative radiotherapy.
METHODS: A total of 296 esophageal squamous cell carcinoma patients receiving preoperative radiotherapy between 1980 and 2007 were included. Patients were staged using the 6th and 7th edition staging systems. Survival analyses were performed using Cox regression models. The homogeneity, discriminatory ability, and monotonicity of gradients of the two staging systems were compared using linear trend χ(2), likelihood ratio statistics, and Akaike information criterion calculation.
RESULTS: The overall five-year survival rate for the entire cohort was 27.1%. Female gender, length, "T," and "N," classifications according to the 7th edition staging system were the prognostic factors in univariate analyses. However, tumor histological grade and cancer location did not significantly influence patient survival. The 7th edition staging system has the highest linear trend χ(2)and likelihood ratio χ(2)scores. Compared to the 6th edition, the 7th edition staging system also has a smaller Akaike information criterion value, which represents the optimum prognostic stratification.
CONCLUSIONS: The strength of the 7th edition AJCC TNM staging system lies in the new descriptors for "T" and "N" classifications. However, we did not find cancer location to be a significant prognostic factor in our cohort. Overall, the 7th edition AJCC TNM staging system performed better than the previous edition.

Entities:  

Keywords:  AJCC cancer stage system; esophageal squamous cell carcinoma; preoperative radiotherapy; prognosis

Year:  2014        PMID: 26767002      PMCID: PMC4704300          DOI: 10.1111/1759-7714.12079

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  12 in total

1.  Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program.

Authors:  S Ueno; G Tanabe; K Sako; T Hiwaki; H Hokotate; Y Fukukura; Y Baba; Y Imamura; T Aikou
Journal:  Hepatology       Date:  2001-09       Impact factor: 17.425

2.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

3.  Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Yun Ku Cho; Jin Wook Chung; Jae Kyun Kim; Yong Sik Ahn; Mi Young Kim; Yoon Ok Park; Wan Tae Kim; Jong Hoon Byun
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

4.  Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.

Authors:  Lucian R Chirieac; Stephen G Swisher; Jaffer A Ajani; Ritsuko R Komaki; Arlene M Correa; Jeffrey S Morris; Jack A Roth; Asif Rashid; Stanley R Hamilton; Tsung-Teh Wu
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

5.  A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.

Authors:  B Dunne; J V Reynolds; E Mulligan; A Kelly; M Griffin
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

6.  Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan.

Authors:  Kwong-Ming Kee; Jing-Houng Wang; Chuan-Mo Lee; Chao-Long Chen; Chi-Sin Changchien; Tsung-Hui Hu; Yu-Fan Cheng; Hsuan-Chih Hsu; Chih-Chi Wang; Tai-Yi Chen; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Int J Cancer       Date:  2007-06-15       Impact factor: 7.396

7.  American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.

Authors:  Nabil P Rizk; Ennapadam Venkatraman; Manjit S Bains; Bernard Park; Raja Flores; Laura Tang; David H Ilson; Bruce D Minsky; Valerie W Rusch
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

Review 8.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

9.  Worldwide esophageal cancer collaboration.

Authors:  T W Rice; V W Rusch; C Apperson-Hansen; M S Allen; L-Q Chen; J G Hunter; K A Kesler; S Law; T E M R Lerut; C E Reed; J A Salo; W J Scott; S G Swisher; T J Watson; E H Blackstone
Journal:  Dis Esophagus       Date:  2009       Impact factor: 3.429

Review 10.  Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities.

Authors:  Christophe Mariette; Guillaume Piessen; Jean-Pierre Triboulet
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316

View more
  5 in total

1.  Prognostic effect of perineural invasion in surgically treated esophageal squamous cell carcinoma.

Authors:  Ha Eun Kim; Seong Yong Park; Hyunki Kim; Dae Joon Kim; Sun Ill Kim
Journal:  Thorac Cancer       Date:  2021-04-03       Impact factor: 3.500

2.  Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma.

Authors:  Qifeng Wang; Bangrong Cao; Junqiang Chen; Chen Li; Lijun Tan; Wencheng Zhang; Jiahua Lv; Xiqing Li; Miyong Xiao; Yu Lin; Jinyi Lang; Tao Li; Zefen Xiao
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

3.  Epiplakin1 promotes the progression of esophageal squamous cell carcinoma by activating the PI3K-AKT signaling pathway.

Authors:  Zhongshi Qiao; Chengcheng Dai; Zhiqian Wang; Zifan Wang; Zheng Wang; Tongsong Zhang; Wenjing Niu; Xuezhen Ma
Journal:  Thorac Cancer       Date:  2022-03-03       Impact factor: 3.223

4.  HIPK3 Promotes Growth and Metastasis of Esophageal Squamous Cell Carcinoma via Regulation of miR-599/c-MYC Axis.

Authors:  Yufeng Ba; Yining Liu; Changsheng Li; Yu Zhu; Wenqun Xing
Journal:  Onco Targets Ther       Date:  2020-03-06       Impact factor: 4.147

5.  FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma.

Authors:  Ying Wang; Zhaojie Lyu; Yanru Qin; Xia Wang; Liangzhan Sun; Yu Zhang; Lanqi Gong; Shayi Wu; Shuo Han; Ying Tang; Yongxu Jia; Dora Lai-Wan Kwong; NgarWoon Kam; Xin-Yuan Guan
Journal:  Theranostics       Date:  2020-09-16       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.